相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Once-weekly semaglutide for obesity or overweight: A systematic review and meta-analysis
Ke He et al.
DIABETES OBESITY & METABOLISM (2022)
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial
Domenica M. Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Qingyang Shi et al.
LANCET (2022)
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Takashi Kadowaki et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Impact of Obesity on In-Hospital Outcomes in Veno-Arterial ECMO Patients
Ilija Djordjevic et al.
HEART LUNG AND CIRCULATION (2022)
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Ping Zhong et al.
ENDOCRINE (2022)
Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
Martin Friedrichsen et al.
DIABETES OBESITY & METABOLISM (2021)
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Young Jin Tak et al.
CURRENT OBESITY REPORTS (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Obesity: Overview of Weight Management
Meetal Mehta et al.
ENDOCRINE PRACTICE (2021)
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
Philip N. Newsome et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study
Mojca Jensterle et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2021)
Obesity: Epidemiology, Pathophysiology, and Therapeutics
Xihua Lin et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis
Kia Vosoughi et al.
ECLINICALMEDICINE (2021)
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Robert F. Kushner et al.
OBESITY (2020)
Obesity in adults: a clinical practice guideline
Sean Wharton et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2020)
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
Gilles R. Dagenais et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines
Thomas Semlitsch et al.
OBESITY REVIEWS (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
Ippei Ikushima et al.
ADVANCES IN THERAPY (2018)
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
Ildiko Lingvay et al.
DIABETES CARE (2018)
Maintenance of Lost Weight and Long-Term Management of Obesity
Kevin D. Hall et al.
MEDICAL CLINICS OF NORTH AMERICA (2018)
Glucagon-like peptide 1 in health and disease
Andreas Andersen et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Glucagon-like peptide- I receptor agonists: a systematic review of comparative effectiveness research
Philip A. Levin et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe
Mika Kivimaki et al.
LANCET PUBLIC HEALTH (2017)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
W. Timothy Garvey et al.
ENDOCRINE PRACTICE (2016)
Weight loss intervention adherence and factors promoting adherence: a meta-analysis
Mark Lemstra et al.
PATIENT PREFERENCE AND ADHERENCE (2016)
Biologic Responses to Weight Loss and Weight Regain: Report From an American Diabetes Association Research Symposium
Rudolph L. Leibel et al.
DIABETES (2015)
European Guidelines for Obesity Management in Adults
Volkan Yumuk et al.
OBESITY FACTS (2015)
Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect
Stephanie Sisley et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Impact of Weight Regain on Metabolic Disease Risk: A Review of Human Trials
Cynthia M. Kroeger et al.
JOURNAL OF OBESITY (2014)
Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice
Benjamin J. Lamont et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Biology's response to dieting: the impetus for weight regain
Paul S. MacLean et al.
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY (2011)
Economic Contextual Factors, Food Consumption, and Obesity among US Adolescents
Lisa M. Powell et al.
JOURNAL OF NUTRITION (2010)
Genome-Wide Association Scan Meta-Analysis Identifies Three Loci Influencing Adiposity and Fat Distribution
Cecilia M. Lindgren et al.
PLOS GENETICS (2009)
Biology of incretins: GLP-1 and GIP
Laurie L. Baggio et al.
GASTROENTEROLOGY (2007)